Local 12: Chemotherapy in recurrent ovarian cancer patients
UC researcher publishes New England Journal of Medicine study looking at outcomes
The five-year survival rate for ovarian cancer is only 36%, one of the worst cancer survival rates out there.
Finding the right treatments, however, is critical to changing that survival rate, according to Dr. Thomas Herzog, a professor at UC and gynecologic oncologist with UC Health. His team just released a study in the New England Journal of Medicine comparing those who just had chemotherapy with a recurrent cancer and those who had chemotherapy in addition to surgery when the cancer came back.
Featured photo courtesy of Unsplash.
Related Stories
UC researchers seek to combat youth weight gain from bipolar medication
September 14, 2026
Cleveland.com highlighted a University of Cincinnati initiative approved for funding by the Patient-Centered Outcomes Research Institute (PCORI) to expand the implementation of healthy lifestyle interventions and metformin prescription to help manage weight gain in overweight or obese youth taking second-generation antipsychotic medications.
UC part of $18 million statewide initiative to expand behavioral health workforce
September 14, 2026
The University of Cincinnati is part of Ohio’s $18 million Behavioral Health Scholarship Program, offering full in-state tuition to eligible social work, mental health counseling and clinical psychology graduate students who commit to serving underserved Ohio communities after graduation.